Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT05916157
Active, not recruiting Observational

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

NCT05916157 · tracked via the Priya Life Science Japan tracker
Sponsor
AbbVie
Phase
Observational
Started
2023-11-30
Last updated
2026-05-15

Condition(s) studied

Parkinson's Disease (PD)

Study summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to assess how safe and effective ABBV-951 is in treating participants with Parkinson's disease in real world setting.

ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan.

Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks.

There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with advanced Parkinson's disease (aPD). * Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD. * Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study. Exclusion Criteria: * Prior treatment with ABBV-951 for PD. * Currently participating in interventional clinical trials.

Primary outcome measure(s)

  • Percentage of Participants Experiencing Infusion Site Infections — Up to 52 Weeks
    Percentage of participants with infusion site infections following the commencement of ABBV-951 will be assessed.

Trial sites (17)

FacilityCityRegionStatus
Saiseikai Matsuyama Hospital /ID# 276259 Matsuyama Ehime
National Hospital Organization Asahikawa Medical Center /ID# 269115 Asahikawa Hokkaido
Hakodate Municipal Hospital /ID# 276757 Hakodate-shi Hokkaido
Ryugasaki Saiseikai Hospital /ID# 264435 Ryūgasaki Ibaraki
University of Tsukuba Hospital /ID# 268353 Tsukuba Ibaraki
Okatsu Hospital /ID# 262781 Kagoshima Kagoshima-ken
University Hospital Kyoto Prefectural University of Medicine /ID# 267445 Kyoto Kyoto
Sendai Nishitaga National Hospital /ID# 268349 Sendai Miyagi
Fujimoto General Hospital /ID# 277287 Miyakonojo-shi Miyazaki
Shiga University of Medical Science Hospital /ID# 265637 Ōtsu Shiga
Dokkyo Medical University Hospital /ID# 269116 Mibu Tochigi
Juntendo University Hospital /ID# 264438 Bunkyo-ku Tokyo
Nitobe Memorial Nakano General Hospital /ID# 275668 Nakano-ku Tokyo
National Center of Neurology and Psychiatry - Kodaira /ID# 267372 Xiaoping City Tokyo
National Hospital Organization Utano Hospital /ID# 268350 Kyoto Japan
Okayama Neurology Clinic /ID# 269117 Okayama Japan
Municipal Toyonaka Hospital /ID# 271277 Toyonaka Japan

More AbbVie trials in Japan

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Active, not recruiting
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Recruiting
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Active, not recruiting

Other trials for the same condition

A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05916157 on ClinicalTrials.gov ↗ ← All trials in Japan